3,4-dichloro-butan-1-ol | 38300-63-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,4-dichloro-butan-1-ol
• 英文别名: 3,4-Dichlor-butan-1-ol；3.4-Dichlor-butylalkohol；1,2-dichloroethane-ethanol；3,4-dichlorobutan-1-ol；1,2-Dichlor-butanol-(4)；3,4-Dichlorbutanol-1
• CAS: 38300-63-9
• 化学式: C₄H₈Cl₂O
• mdl: MFCD19232445
• 分子量: 143.013
• InChiKey: COPNBMBEZMJJPT-UHFFFAOYSA-N

物化性质

• 沸点：
  90-92 °C(Press: 6 Torr)
• 密度：
  1.2855 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,4-dichloro-butan-1-ol 在 氯化亚砜 作用下， 生成 1,2,4-三氯丁烷
  参考文献：
  名称：

  Farberow; Ustawschtschikow, Zhurnal Obshchei Khimii, 1955, vol. 25, p. 2071,2079;engl.Ausg.S.2025,2032

  摘要：

  DOI：
• 作为产物：
  描述：

  3-丁烯-1-醇 在 Oxone 、 sodium chloride 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.5h， 以99%的产率得到3,4-dichloro-butan-1-ol
  参考文献：
  名称：

  方便地从酮和氯中原位生成各种二氯试剂：烯丙基和均烯丙基醇衍生物的非对映选择性二氯化†

  摘要：

  安全且方便的方案是为开发原位生成各种dichlorinating剂的（CF Cl为2，的NCI 3等4的NCI 3，ArICl 2）从酮和氯化物。该协议的合成效用通过一系列具有优异收率和非对映选择性的烯丙基和均烯丙基醇衍生物的非对映选择性二氯化反应得到证明。

  DOI：

  10.1039/c3ob40670a

文献信息

• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Bergmann John E.

  公开号：US20080300240A1

  公开（公告）日：2008-12-04

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R 1 , R 2 , R 3 , R 4 , R 5 , A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE 10 in a warm-blooded animal in need of the same.

  抑制PDE10的化合物已被披露，对治疗包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病（如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑瘫、睡眠障碍、疼痛、抽动症、精神分裂症、妄想症、药物诱发的精神病和恐慌以及强迫症）多种疾病具有用途。这些化合物具有一般结构： 其中m、n、p、x、R、R1、R2、R3、R4、R5、A和B在此定义，包括药学上可接受的盐、立体异构体、溶剂合物或其前药。还披露了含有本发明化合物的组合物，与药学上可接受的载体结合，以及与使用这些化合物抑制需要同样的PDE10的温血动物相关的方法。
• Method for producing a fluorinated ester compound
  申请人：ASAHI GLASS COMPANY LIMITED

  公开号：US20030216595A1

  公开（公告）日：2003-11-20

  The present invention provides a method for producing industrially useful fluorine-containing compounds such as a fluorinated ester compound and an acid fluoride compound. Namely, the present invention resides in a method for producing a fluorinated ester compound, which comprises fluorinating an ester compound which is an ester of a compound having hydroxyl group(s) with a compound having acyl fluoride group(s) and which has a structure which can be fluorinated, in a liquid phase to produce a fluorinated ester compound, wherein the fluorination is carried out in the form of a liquid mixture of the ester compound and the compound having acyl fluoride group(s).

  本发明提供了一种生产工业上有用的含氟化合物，如含氟酯化合物和酸氟化合物的方法。 即，本发明涉及一种生产含氟酯化合物的方法，包括在液相中将含有羟基的化合物的酯与含有酰氟基的化合物氟化，以产生含氟酯化合物，其中氟化是以酯化合物和含有酰氟基的化合物的液相混合物的形式进行的。
• DPP-IV inhibitors
  申请人：Santhera Pharmaceuticals (Schweiz) GmbH

  公开号：EP1702916A1

  公开（公告）日：2006-09-20

  The invention relates to compounds of formula (I) wherein Z, R1-7, X and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z、R1-7、X和n的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及其作为药物的生产和使用。
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS DPP- IV INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES COMME INHIBITEURS DE LA DPP-IV
  申请人：SANTHERA PHARMACEUTICALS CH

  公开号：WO2006013104A1

  公开（公告）日：2006-02-09

  The invention relates to compounds of formula Z-C(R1R2)-C(R3NH2)-C(R4R5)-A (I) wherein Z, R1-R5 and A have the meaning as cited in the description and the claims as examplified by the compound (II) said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及公式Z-C(R1R2)-C(R3NH2)-C(R4R5)-A（I）的化合物，其中Z，R1-R5和A的含义如描述和权利要求所述，并以化合物（II）为例。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及其作为药物的生产和使用。
• Process for producing a fluorine-containing compound by liquid phase fluorination
  申请人：ASAHI GLASS COMPANY, LIMITED

  公开号：US20030204099A1

  公开（公告）日：2003-10-30

  The invention provides a process for producing a fluorine-containing compound from an inexpensive material. Namely, Compound I such as R A CH 2 OH is reacted with Compound II such as XCOR B to form Compound III such as R A CH 2 OCOR B , followed by fluorination in a liquid phase to form Compound IV such as R AF CF 2 OCOR BF , which is converted to Compound V such as R AF COF and/or Compound VI such as R BF COF. R A is an alkyl group or the like, R B is a perhalogenoalkyl group or the like, R AF and R BF are fluorinated R A and R B , and X is halogen.

  本发明提供了一种从廉价材料制备含氟化合物的方法。即，将化合物I，如RACH2OH，与化合物II，如XCORB，反应形成化合物III，如RACH2OCORB，然后在液相中进行氟化反应形成化合物IV，如RAFCF2OCORBF，然后将其转化为化合物V，如RAFCOF和/或化合物VI，如RBFCOF。其中，RA是烷基或类似物，RB是全氟烷基或类似物，RAF和RBF是氟化的RA和RB，X是卤素。